Antibiotic exposure and growth patterns in preterm, very low birth weight infants

Alaina K Pyle1,2, Joseph B Cantey1,3, L Steven Brown4

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Insights

Antibiotic exposure in preterm infants was not linked to altered growth up to 12 months corrected age. Neonatal morbidities may influence outcomes more than antibiotic use in very-low-birth-weight infants.

Area of Science:

  • Neonatal research
  • Pediatric growth studies
  • Antibiotic impact analysis

Background:

  • Antibiotic exposure in term infants is linked to later obesity.
  • Preterm, very-low-birth-weight infants in NICU settings often receive antibiotics.
  • This study investigated antibiotic exposure and growth in preterm infants.

Purpose of the Study:

  • To determine if antibiotic exposure in preterm infants correlates with growth.
  • To test for a dose-dependent relationship between antibiotic use and infant growth.
  • To analyze growth from birth to 12 months corrected age.

Main Methods:

  • Retrospective analysis of prospectively collected data.
  • Included preterm (≤32 weeks gestation), very-low-birth-weight infants.
  • Quantified antibiotic use by days of therapy and compared with growth parameters.

Main Results:

  • 161 infants received a median of 11 antibiotic days of therapy.
  • No association found between antibiotic exposure and weight or length changes.
  • Growth delta z-scores were not significantly affected by antibiotic duration.

Conclusions:

  • Prolonged antibiotic use may not be associated with increased weight gain in preterm infants.
  • Neonatal morbidities and mortality might outweigh antibiotic effects on growth.
  • Further research needed to clarify complex NICU infant outcomes.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
106
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
102
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
128
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
584
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
103